The Medsintez Plant took part in the IX (XXVIII) National Diabetes Congress in Moscow

From September 5 to 8, 2022, the IX (XXVIII) National Diabetes Congress with international participation Diabetes Mellitus and Obesity – the Non-Infectious Interdisciplinary Pandemics of the 21st Century was held in Moscow, organized by the Russian Association of Endocrinologists and the Federal State Budgetary Institution National Medical Research Center for Endocrinology of the Ministry of Health of Russia. Among the leading domestic and foreign companies producing medicines, the Medsintez Plant presented its main products at the booth – preparations of genetically engineered and analogue human insulin Rosinsulin.

The Medsintez Plant is one of the first industrial production facilities in Russia for finished dosage forms of genetically engineered human insulin that meet the requirements of GMP EC. Since 2009, the Medsintez Plant has been providing the country with high-quality insulin preparations, being an active participant in the implementation of import substitution programs for medicines in the Russian Federation for all these years. The enterprise implements a full cycle of production of genetically engineered and analogue human insulin Rosinsulin produced in the most convenient and familiar dosage forms for consumers – in vials, cartridges and syringe pens.

To date, as part of the project of Import-substituting production of genetically engineered and analogue insulin from its own substance, the Medsintez Plant has launched the production of the entire line of genetically engineered human insulin preparations Rosinsulin Medsintez and the analogue insulin preparation Rosinsulin Aspart R from its own substance, the decision of the Ministry of Health of the Russian Federation to add its own analogue medicine, Rosinsulin Glargine (100 IU/ml), to the State Register of Medicines is also expected. An analogue medicine Rosinsulin Glargine 300 Medsintez with a concentration of 300 IU/ml has also been developed.

High-tech Russian production at the Medsintez Plant ensures a world-class level of quality and safety of manufactured medicines. The production of insulin from its own substance allows us to completely abandon purchases from foreign companies, gain independence from currency fluctuations, and therefore offer a favorable price for the finished preparation in comparison with imported analogues. The production capacity of the Medsintez Plant makes it possible to satisfy 100% of Russia's demand for insulin preparations.

As part of the business program of the Congress, leading experts in the field of endocrinology: members of the Russian Academy of Sciences, heads of healthcare institutions, representatives of medical universities and pharmaceutical companies made presentations and discussed about thirty important topics in fundamental diabetology, modern methods of diagnosing and treating endocrine diseases, training programs for patients with diabetes mellitus and many others. Also, draft national clinical guidelines were presented at the Congress.

The National Diabetes Congress Diabetes Mellitus and Obesity – the Non-Infectious Interdisciplinary Pandemics of the 21st Century is a project of the educational segment of the Grant of the Ministry of Science and Higher Education of the Russian Federation Program for the Creation and Development for 2020-2025 of the National Center for Personalized Medicine for Endocrine Diseases, in which representatives of the Medsintez Plant traditionally took part.